Active substanceInosineInosine
Similar drugsTo uncover
  • Inosie-F®
    solution in / in 
    Europharm (UK) Co., Ltd.     United Kingdom
  • Inosine
    solution in / in 
    Ama Pharm, OOO     China
  • Inozin-Eskom
    solution in / in 
    ESKOM NPK, OAO     Russia
  • Riboxin
    solution in / in 
    ATOLL, LLC     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    solution in / in 
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    MAKSFARM, OJSC     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    BINNOFARM, CJSC     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    OZONE, LLC     Russia
  • Riboxin
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Riboxin
    solution in / in 
    BIOSINTEZ, PAO     Russia
  • Riboxin
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Riboxin
    capsules inwards 
    MINSKINTERKAPS, UP     Republic of Belarus
  • Riboxin
    solution in / in 
    VEROPHARM SA     Russia
  • Riboxin
    pills inwards 
    Mapichem AG     Switzerland
  • Riboxin
    solution in / in 
    Mapichem AG     Switzerland
  • Riboxin
    solution in / in 
    DALHIMFARM, OJSC     Russia
  • Riboxin
    solution in / in 
    ELLARA, LTD.     Russia
  • Riboxin
    solution in / in 
    GROTEKS, LLC     Russia
  • Riboxin
    solution in / in 
    VELFARM, LLC     Republic of San Marino
  • Riboxin of Avexime
    pills inwards 
  • Riboxin Beefus
    solution in / in 
    UPDATE OF PFC, CJSC     Russia
  • Riboxin-Vial
    solution in / in 
    VIAL, LLC     Russia
  • Riboxin-LexT
    pills inwards 
  • Riboxin-Ferein
    pills inwards 
    BRYNTSALOV-A, CJSC     Russia
  • ASFARMA, LLC     Russia
  • Dosage form: & nbspsolution for intravenous administration
    Composition:

    Active substance:

    inosine - 20.0 mg

    Excipient:

    sodium hydroxide 2.2 mg

    water for injection - up to 1 ml

    Description:
    Transparent, colorless or slightly yellowish liquid.
    Pharmacotherapeutic group:Metabolic means
    ATX: & nbsp

    C.01.E.B   Other drugs for the treatment of heart disease

    Pharmacodynamics:Metabolic agent, a precursor of adenosine triphosphate (ATP); has antihypoxic, metabolic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative kidney ischemia. It takes a direct part in the exchange of glucose and promotes the activation of metabolism in conditions of hypoxia and in the absence of ATP. Activates the metabolism of pyruvic acid to ensure a normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides. enhances the activity of certain enzymes of the Krebs cycle. Penetrating into cells, increases the energy level, has a positive effect on the metabolic processes in the myocardium, increases the strength of the heart contractions and promotes more complete relaxation of the myocardium in diastole, resulting in an increase in the shock volume of blood. Reduces platelet aggregation, activates the regeneration of tissues (especially the myocardium and mucous membrane
    gastrointestinal tract (GIT)).
    Pharmacokinetics:Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount, it is excreted by the kidneys.
    Indications:

    Complex treatment of myocardial infarction; ischemic heart disease; disorders of the heart rhythm, caused by the use of cardiac glycosides, against the background of myocardial dystrophy after the infectious diseases. Diseases of the liver (hepatitis, cirrhosis, fatty degeneration).

    Operations on an isolated kidney (as a means of pharmacological protection in the short-term shutdown of the circulatory system of the operated organ).

    Contraindications:Hypersensitivity, gout, hyperuricemia, the period of breastfeeding, pregnancy, age of 18 years (efficacy and safety not established).
    Carefully:Renal failure.
    Pregnancy and lactation:It is not recommended to use during pregnancy and during breastfeeding.
    Dosing and Administration:

    Intravenously injected slowly (40-60 drops per minute) drip or jet. Initially, 200 mg (10 ml of a 2% solution) are administered once a day, in the following periods with good tolerability - up to 400 mg (20 ml of 2% solution) 1-2 times a day. The course of treatment is 10-15 days.

    Jet injection is possible for acute heart rhythm disorders in a single dose of 200-400 mg (10-20 ml of a 2% solution).

    When drip into the vein, 2% solution of the drug is diluted in 5% glucose solution or isotonic sodium chloride solution (up to 250 ml).

    For pharmacological protection of the kidneys subjected to ischemia, inosine is injected intravenously in a single dose of 1200 mg (60 ml of a solution of 20 mg / ml) 5-15 minutes before the compression of the renal artery, and then additionally 800 mg (40 ml of 20 mg / ml solution) immediately after the restoration of blood circulation.

    Side effects:When using inosine, individual intolerance is possible, manifested by itching, flushing of the skin. Rarely the concentration of uric acid in the blood increases. Perhaps an exacerbation of gout (prolonged use).
    Overdose:At present, no cases of overdose have been reported.
    Interaction:When combined with cardiac glycosides, the drug can prevent the occurrence of arrhythmias, enhance the positive inotropic effect. Immunosuppressants reduce the effectiveness of inosine.
    Special instructions:When itching and hyperemia of the skin, treatment with the drug should be discarded.During prolonged treatment it is desirable to control the level of uric acid in the blood and urine.
    Effect on the ability to drive transp. cf. and fur:The drug does not adversely affect the ability to drive vehicles and perform other potentially dangerous activities that require increased concentration and speed of psychomotor reactions.
    Form release / dosage:
    Solution for intravenous administration, 20 mg / ml.
    Packaging:
    5 or 10 ml into neutral glass ampoules (type HC-3) with a notch, dot or without a notch. 5 or 10 ampoules are placed in a contour mesh package made of a polyvinyl chloride film. 1 circuit cell pack together with the instruction for use and the ampoule scarifier are placed in a cardboard box.
    Storage conditions:In the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:3 years. Do not use after expiry date.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-003651
    Date of registration:26.05.2016
    Expiration Date:26.05.2021
    The owner of the registration certificate:Ama Pharm, OOOAma Pharm, OOO China
    Manufacturer: & nbsp
    Representation: & nbspAma Pharm, OOOAma Pharm, OOORussia
    Information update date: & nbsp31.10.2017
    Illustrated instructions
      Instructions
      Up